AVE 1625

Discontinued Product

6763 has been discontinued.

View all CB<sub>1</sub> Receptors products.
Description: Potent and selective CB1 receptor antagonist
Alternative Names: Drinabant
Chemical Name: N-[1-[Bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)methanesulfonamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (2)

Biological Activity for AVE 1625

AVE 1625 is a potent and selective CB1 receptor antagonist (IC50 values are 25 and 10 nM for human and rat CB1R, respectively). Exhibits >400-fold selectivity for CB1 over CB2 receptors. Attenuates Olanzapine (Cat. No. 4349) induced weight gain and food intake in rats with no effect on energy expenditure or motility. Also improves cognitive function in rodent schizophrenia models and ameliorates extrapyramidal side-effects of antipsychotics.

Technical Data for AVE 1625

M. Wt 497.38
Formula C23H20Cl2F2N2O2S
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 358970-97-5
PubChem ID 10278470
InChI Key IQQBRKLVEALROM-UHFFFAOYSA-N
Smiles CS(=O)(N(C1=CC(F)=CC(F)=C1)C2CN(C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)C2)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for AVE 1625

References are publications that support the biological activity of the product.

Herling et al (2007) CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am.J.Physiol.Endocrinol.Metab. 293 E826 PMID: 17595216

Liebig et al (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity 18 1952 PMID: 20168311

Black et al (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl.) 215 149 PMID: 21181124

View Related Products by Target

View Related Products by Product Action

View all CB1 Receptor Antagonists

Keywords: AVE 1625, AVE 1625 supplier, AVE1625, cannabinoid, receptor, antagonist, potent, selective, CB1, CB1R, anti-obesity, Drinabant, Receptors, 6763, Tocris Bioscience

Citations for AVE 1625

Citations are publications that use Tocris products.

Currently there are no citations for AVE 1625.

Reviews for AVE 1625

There are currently no reviews for this product. Be the first to review AVE 1625 and earn rewards!

Have you used AVE 1625?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cannabinoid Receptor Ligands Scientific Review

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.